SLC5A2 and hydrops fetalis: Experimental data have suggested that SGLT-2 inhibitor-mediated improvement in LV diastolic function results in lower filling pressures, which, along with induced amelioration in myocardial stiffness and fibrosis, leads to better LV performance and might to some extent explain the beneficial results of this class in HF [32].